A Broad‐Spectrum Tumor‐Penetrating Peptide WKASC: Design, Screening, and Platform Development for Cancer Therapy
Small · 2026-11 · 22 (61)
DOI: 10.1002/smll.75785 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 16.09.2026. Verfasst von Yichen Tian und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Chemical Engineering, College of Materials Science and Engineering, Institute of Biomedical Materials and Engineering, Qingd…. Hauptthemen laut MEDLINE: Cell-Penetrating Peptides, Neoplasms. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Shandong Provincial Natural Science Foundation.
Abstract (Originalsprache)
Conventional cancer therapies are often limited by inadequate drug accumulation in tumors, drug resistance, and systemic toxicity. Cell‐penetrating peptides (CPPs) offer a promising strategy to enhance intracellular drug delivery. In this study, we designed a novel tumor‐penetrating peptide, P3 (sequence: Trp‐Lys‐Ala‐Ser‐Cys), which demonstrated exceptional transmembrane efficiency with a broad‐spectrum penetration profile across various tumor cell lines (including HeLa, HGC‐27, and A549 etc.). Notably, it achieved an internalization rate of 47.4% in A549 cells within 15 min. This peptide was further engineered into an amphiphilic polymer, P3‐Mal‐PEG‐PCL, which self‐assembled into pH‐responsive micelles. Doxorubicin (DOX) was encapsulated within these micelles to form DOX@P3P, which was subsequently coated with hyaluronic acid (HA) to create the final actively targeted nanoparticles, DOX@P3P@HA (PHA NPs), leveraging the cluster of differentiation 44 (CD44) receptor overexpression on cancer cells. The PHA NPs displayed excellent biosafety, colloidal stability, and improved drug distribution. In a murine tumor model, treatment with PHA NPs resulted in a remarkable 76.6% reduction in tumor volume, underscoring its potent antitumor efficacy and highlighting its potential as a robust platform for targeted cancer chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chemistry and Chemical Engineering, College of Materials Science and Engineering, Institute of Biomedical Materials and Engineering, Qingdao University, Qingdao, China.
- College of Chemistry, Chemical Engineering and Materials Science, Zaozhuang University, Zaozhuang, China.
- School of Materials Science and Engineering, Shandong University of Technology, Zibo, China.
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Shandong Provincial Natural Science Foundation
- Qingdao Science and Technology for People's Benefit Demonstration Project
- Science and Technology Planing Project of South District of Qingdao City
- Exploration project of the State Key Laboratory of BioFibers and EcoTextiles of Qingdao University
- Medical Plus Key Project of Qingdao University
- Natural Science Foundation of Shandong Province
Zitieren
APA
Tian, Y., Li, Y., Cao, M., Wang, Q., Xu, M., Li, W., Cong, H., & Yu, B. (2026). A Broad‐Spectrum Tumor‐Penetrating Peptide WKASC: Design, Screening, and Platform Development for Cancer Therapy. Small, 22(61). https://doi.org/10.1002/smll.75785
Vancouver
Tian Y, Li Y, Cao M, Wang Q, Xu M, Li W, et al. A Broad‐Spectrum Tumor‐Penetrating Peptide WKASC: Design, Screening, and Platform Development for Cancer Therapy. Small. 2026;22(61). doi:10.1002/smll.75785
BibTeX
@article{Tian2026,
author = {Tian, Yichen and Li, Yanan and Cao, Mengyu and Wang, Qinao and Xu, Mengyuan and Li, Wenjie and Cong, Hailin and Yu, Bing},
title = {A Broad‐Spectrum Tumor‐Penetrating Peptide WKASC: Design, Screening, and Platform Development for Cancer Therapy},
journal = {Small},
year = {2026},
volume = {22},
number = {61},
doi = {10.1002/smll.75785}
}
EUVIMED